Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Genistein (NPI-031L; BIO-300; G-2535; PTI-G-4660; SIPI-9764I), a naturally occuring isoflavonoid isolated from soy products, is a potent multi-kinase inhibitor with potential anticancer activity against various cancers. Additionally, it is a phytoestrogen with selective estrogen receptor modulator effects on the estrogen receptors. Numerous additional biological activities, like those of an anthelmintic and antioxidant, are also present.
Targets |
EGFR; topo II
|
||
---|---|---|---|
ln Vitro |
|
||
ln Vivo |
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C15H10O5
|
---|---|
Molecular Weight |
270.24
|
Exact Mass |
270.05
|
Elemental Analysis |
C, 66.67; H, 3.73; O, 29.60
|
CAS # |
446-72-0
|
Related CAS # |
Genistein;446-72-0
|
Appearance |
Solid powder
|
SMILES |
C1=CC(=CC=C1C2=COC3=CC(=CC(=C3C2=O)O)O)O
|
InChi Key |
TZBJGXHYKVUXJN-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-13-6-10(17)5-12(18)14(13)15(11)19/h1-7,16-18H
|
Chemical Name |
5,7-dihydroxy-3-(4-hydroxyphenyl)chromen-4-one
|
Synonyms |
NPI 031L; NPI031L; NPI-031L; BIO-300; G-2535; PTI-G-4660; SIPI-9764-I; PTIG-4660; SIPI-9764I; BIO300; G2535; PTIG4660; SIPI9764I; BIO 300; G 2535; PTI G 4660; SIPI 9764 I; PTIG 4660; SIPI 9764I; Genistein
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (13.88 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (11.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3 mg/mL (11.10 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 5 mg/mL (18.50 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.7004 mL | 18.5021 mL | 37.0041 mL | |
5 mM | 0.7401 mL | 3.7004 mL | 7.4008 mL | |
10 mM | 0.3700 mL | 1.8502 mL | 3.7004 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT01489813 | Active Recruiting |
Drug: Genistein Drug: Sugar pill |
Bladder Cancer | Emory University | May 19, 2017 | Phase 2 |
NCT04482595 | Recruiting | Drug: BIO 300 Oral Suspension Drug: Placebo |
COVID-19 Long COVID |
Humanetics Corporation | November 11, 2020 | Phase 2 |
NCT01985763 | Completed | Drug: Genistein | Colon Cancer Rectal Cancer |
Sofya Pintova | November 2013 | Phase 1 Phase 2 |
NCT01982578 | Completed | Dietary Supplement: Genistein Other: Placebo |
Alzheimer's Disease | Fundación para la Investigación del Hospital Clínico de Valencia |
September 1, 2017 | Not Applicable |
NCT02624388 | Terminated | Drug: Genistein Drug: Placebo |
Lymphoma Solid Tumor |
University of Virginia | August 2016 | Phase 2 |
Effects of genistein on osteogenesis in KS483 cells. J Biol Chem . 2003 Jan 10;278(2):962-7. td> |
Effects of genistein on osteogenesis in mouse bone marrow cells. J Biol Chem . 2003 Jan 10;278(2):962-7. td> |
Effects of genistein on adipogenesis in KS483 cells and in mouse bone marrow cells. J Biol Chem . 2003 Jan 10;278(2):962-7. td> |